This HTML5 document contains 197 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
dbpedia-de	http://de.dbpedia.org/resource/
dbpedia-sh	http://sh.dbpedia.org/resource/
dbpedia-cy	http://cy.dbpedia.org/resource/
dct	http://purl.org/dc/terms/
yago-res	http://yago-knowledge.org/resource/
dbo	http://dbpedia.org/ontology/
n15	http://dbpedia.org/resource/File:
foaf	http://xmlns.com/foaf/0.1/
dbpedia-ko	http://ko.dbpedia.org/resource/
n13	https://global.dbpedia.org/id/
umbel-rc	http://umbel.org/umbel/rc/
yago	http://dbpedia.org/class/yago/
dbt	http://dbpedia.org/resource/Template:
n31	http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/
rdfs	http://www.w3.org/2000/01/rdf-schema#
n35	http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebase	http://rdf.freebase.com/ns/
dbpedia-sr	http://sr.dbpedia.org/resource/
dbpedia-pl	http://pl.dbpedia.org/resource/
n18	https://druginfo.nlm.nih.gov/drugportal/name/
n17	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/
dbpedia-fi	http://fi.dbpedia.org/resource/
dbpedia-fa	http://fa.dbpedia.org/resource/
n14	http://commons.wikimedia.org/wiki/Special:FilePath/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
owl	http://www.w3.org/2002/07/owl#
dbpedia-fr	http://fr.dbpedia.org/resource/
dbpedia-zh	http://zh.dbpedia.org/resource/
wikipedia-en	http://en.wikipedia.org/wiki/
dbp	http://dbpedia.org/property/
dbc	http://dbpedia.org/resource/Category:
prov	http://www.w3.org/ns/prov#
xsdh	http://www.w3.org/2001/XMLSchema#
wikidata	http://www.wikidata.org/entity/
gold	http://purl.org/linguistics/gold/
n34	http://api.nytimes.com/svc/semantic/v2/concept/name/nytd_des/
dbr	http://dbpedia.org/resource/

Statements

Subject Item

dbr:Midodrine

rdf:type

yago:Formula106816935 yago:OrganicCompound114727670 yago:Quintessence114847103 yago:MolecularFormula106817173 yago:Relation100031921 owl:Thing yago:WikicatPhenolEthers yago:Communication100033020 yago:Acetamide114711197 yago:Message106598915 yago:Element114840755 umbel-rc:DrugProduct yago:Abstraction100002137 yago:Part113809207 yago:WikicatAcetamides yago:AliphaticCompound114601294 yago:WikicatMolecularFormulas yago:Substance100019613 yago:WikicatCardiacStimulants yago:Chemical114806838 yago:Material114580897 yago:Amine114739004 yago:Amide114724264 yago:MethaneSeries114951377 yago:Compound114818238 dbo:Drug yago:Information105816287 yago:PhysicalEntity100001930 yago:Cognition100023271 yago:Matter100020827 wikidata:Q8386 yago:PsychologicalFeature100023100 yago:WikicatAmines n35:ChemicalObject yago:Statement106722453 dbo:ChemicalSubstance yago:Stimulation105827684

rdfs:label

Midodrine 邁妥林 Midodrine 미도드린 Midodryna Midodrin

rdfs:comment

Midodrine is a vasopressor/antihypotensive agent (it raises the blood pressure). Midodrine was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of dysautonomia and orthostatic hypotension. In August 2010, the FDA proposed withdrawing this approval because the manufacturer, Shire plc, failed to complete required studies after the medicine reached the market. In September 2010, the FDA reversed its decision to remove midodrine from the market and allowed it to remain available to patients while Shire plc collected further data regarding the efficacy and safety of the drug. Shire announced on September 22, 2011, that it was withdrawing completely from supplying midodrine and leaving it to several generics to supply the drug. Midodrin (Handelsname Gutron®) ist ein Arzneistoff, der zur Behandlung von hypotonen Kreislaufstörungen (orthostatische Hypotonie) dient. Es handelt sich dabei um ein Prodrug, dessen Metabolit Desglymidodrin den eigentlichen Wirkstoff darstellt. Der Arzneistoff wird in Form seines Hydrochlorids angewandt. La midodrine (par exemple Amatine, ProAmatine, Gutron) est un médicament vasopresseur, antihypotensif. Elle se présente sous forme de poudre cristalline blanche, inodore, soluble dans l'eau, peu soluble dans le méthanol. Midodryna (midodrin) – organiczny związek chemiczny stosowany jako lek z grupy sympatykomimetyków. Jest związkiem chiralnym, produkt farmaceutyczny jest mieszaniną racemiczną obu enancjomerów Przekształcany w organizmie na drodze hydrolizy enzymatycznej do właściwej substancji czynnej – deglimidodryny, która z kolei pobudza receptory adrenergiczne α1. Działa wyłącznie na receptory obwodowe, nie ma wpływu na receptory β-adrenergiczne mięśnia sercowego. Jej działanie odpowiada zasadniczo działaniu innych leków alfa-sympatykomimetycznych. Po jej podaniu dochodzi do zwiększenia skurczowego i rozkurczowego ciśnienia krwi, jak również do odruchowej bradykardii. Wzrost ciśnienia jest skutkiem obkurczenia drobnych żył i tętniczek, czyli zwiększenia oporu obwodowego. 邁妥林是血管加压 / 抗低血压藥物，在1996年被美国食品药品监督管理局 （FDA）批准用于治疗自主神经功能障碍和姿位性低血压 。 FDA在2010年8月提议撤回该核准，因为制造商Shire plc在药物上市後后未能完成所需的研究 。 2010年9月，Shire plc收集了有关该药效果和安全性的进一步数据，FDA撤回上述提議並允许其继续供患者使用。 Shire plc于2011年9月27日宣布，它将继续与FDA合作以最终批准该药物。 미도드린(midodrine)은 혈압을 높이는 승압제, 이다. 미도드린은 1996년 미국 식품의약국(FDA)에서 과 기립성 저혈압 치료제로 승인되었다. 2010년 8월 FDA는 제조업체인 Shire plc가 약물이 시장에 출시된 후 필요한 를 완료하지 못했기 때문에 이 승인을 철회할 것을 제안했다. 2010년 9월 FDA는 시장에서 미도드린을 제거하기로 한 결정을 번복하고 환자가 계속 사용할 수 있도록 허용했으며, Shire plc는 약물의 효능과 안전성에 관한 추가 데이터를 수집했다. Shire는 2011년 9월 22일에 미도드린 공급을 완전히 중단하고 약물의 공급은 여러 에 맡긴다고 발표했다.

foaf:depiction

n14:Midodrine.svg n14:Midodrine_synthesis.svg n14:(R)-Midodrin_Structural_Formula_V1.svg n14:(S)-Midodrin_Structural_Formula_V1.svg n14:Desglymidodrine.svg

dct:subject

dbc:Alpha-1_adrenergic_receptor_agonists dbc:Phenol_ethers dbc:Phenylethanolamines dbc:Prodrugs dbc:Cardiac_stimulants dbc:Peripherally_selective_drugs dbc:Acetamides

dbo:wikiPageID

2294312

dbo:wikiPageRevisionID

1119963014

dbo:wikiPageWikiLink

dbr:Metabolite n15:Midodrine_synthesis.svg dbr:Enantiomer dbr:1,4-dimethoxybenzene dbr:Methanol dbr:Postmarketing_surveillance dbr:Chloroacetyl_chloride dbr:Alpha-1_adrenergic_receptor dbr:Dysautonomia dbr:Vasopressor dbr:Cirrhosis dbr:Orthostatic_hypotension dbr:Racemic_mixture dbr:Pheochromocytoma dbr:Kidney_dialysis dbr:Blood–brain_barrier dbr:Alpha-adrenergic_receptor dbc:Alpha-1_adrenergic_receptor_agonists dbr:Urinary_retention dbr:Beta-adrenergic_receptor dbr:Desglymidodrine dbr:Prodrug dbr:Food_and_Drug_Administration dbr:Octreotide dbc:Phenol_ethers dbr:Thyrotoxicosis dbr:Central_nervous_system dbr:Pruritus dbr:Agonist dbr:Droxidopa dbc:Phenylethanolamines dbr:Shire_plc dbr:Racemate dbc:Cardiac_stimulants dbr:Hepatorenal_syndrome dbc:Prodrugs n15:(R)-Midodrin_Structural_Formula_V1.svg n15:(S)-Midodrin_Structural_Formula_V1.svg n15:Desglymidodrine.svg dbr:Oral_administration dbc:Peripherally_selective_drugs dbr:Neurogenic_orthostasis dbr:Antihypotensive dbr:Goose_bumps dbc:Acetamides

dbo:wikiPageExternalLink

n18:midodrine

owl:sameAs

wikidata:Q415051 dbpedia-fa:میدودرین n13:3qnRc dbpedia-fi:Midodriini n17:DB00211 dbpedia-fr:Midodrine dbpedia-sr:Midodrin dbpedia-zh:邁妥林 dbpedia-pl:Midodryna yago-res:Midodrine dbpedia-de:Midodrin dbpedia-sh:Midodrin n31:4195 dbpedia-ko:미도드린 dbpedia-cy:Midodrin n34:Midodrine%20(Drug) freebase:m.071kv2

dbp:wikiPageUsesTemplate

dbt:Reflist dbt:Fdacite dbt:Short_description dbt:Adrenergic_receptor_modulators dbt:Stdinchicite dbt:Keggcite dbt:Drugs.com dbt:Unreferenced_section dbt:Cascite dbt:Chemspidercite dbt:Commons_category-inline dbt:Use_dmy_dates dbt:Ebicite dbt:Clear_left dbt:Cardiac_stimulants_excluding_cardiac_glycosides dbt:Portal_bar dbt:Cite_web dbt:Drugbankcite dbt:Drugbox

dbo:thumbnail

n14:Midodrine.svg?width=300

dbp:atcSuffix

CA17

dbp:atcPrefix

1.0

dbp:c

12

dbp:casNumber

42794

dbp:chebi

6933

dbp:chembl

1076

dbp:chemspiderid

4050

dbp:drugbank

DB00211

dbp:h

18

dbp:iupacName

- N-[2--2-hydroxyethyl]glycinamide

dbp:kegg

D08220

dbp:legalUs

Rx-only

dbp:medlineplus

a602023

dbp:n

2

dbp:o

4

dbp:pubchem

4195

dbp:routesOfAdministration

dbr:Oral_administration

dbp:smiles

O=CCN

dbp:stdinchi

1

dbp:stdinchikey

PTKSEFOSCHHMPD-UHFFFAOYSA-N

dbp:synonyms

(2-amino-N-[2--2-hydroxy-ethyl]-acetamide)

dbp:tradename

Amatine, Proamatine, Gutron, others

dbp:unii

6

dbp:verifiedfields

changed

dbp:verifiedrevid

462252266

dbp:watchedfields

changed

dbp:width

200

dbo:abstract

Midodryna (midodrin) – organiczny związek chemiczny stosowany jako lek z grupy sympatykomimetyków. Jest związkiem chiralnym, produkt farmaceutyczny jest mieszaniną racemiczną obu enancjomerów Przekształcany w organizmie na drodze hydrolizy enzymatycznej do właściwej substancji czynnej – deglimidodryny, która z kolei pobudza receptory adrenergiczne α1. Działa wyłącznie na receptory obwodowe, nie ma wpływu na receptory β-adrenergiczne mięśnia sercowego. Jej działanie odpowiada zasadniczo działaniu innych leków alfa-sympatykomimetycznych. Po jej podaniu dochodzi do zwiększenia skurczowego i rozkurczowego ciśnienia krwi, jak również do odruchowej bradykardii. Wzrost ciśnienia jest skutkiem obkurczenia drobnych żył i tętniczek, czyli zwiększenia oporu obwodowego. Ze względu na lokalizację receptorów α1-adrenergicznych, midodryna działa lokalnie, głównie w mięśniu sercowym i w nerkach oraz pęcherzu, gdzie zwiększa napięcie mięśniowe zwieracza pęcherza i tym samym opóźnia jego opróżnianie się. 미도드린(midodrine)은 혈압을 높이는 승압제, 이다. 미도드린은 1996년 미국 식품의약국(FDA)에서 과 기립성 저혈압 치료제로 승인되었다. 2010년 8월 FDA는 제조업체인 Shire plc가 약물이 시장에 출시된 후 필요한 를 완료하지 못했기 때문에 이 승인을 철회할 것을 제안했다. 2010년 9월 FDA는 시장에서 미도드린을 제거하기로 한 결정을 번복하고 환자가 계속 사용할 수 있도록 허용했으며, Shire plc는 약물의 효능과 안전성에 관한 추가 데이터를 수집했다. Shire는 2011년 9월 22일에 미도드린 공급을 완전히 중단하고 약물의 공급은 여러 에 맡긴다고 발표했다. Midodrine is a vasopressor/antihypotensive agent (it raises the blood pressure). Midodrine was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of dysautonomia and orthostatic hypotension. In August 2010, the FDA proposed withdrawing this approval because the manufacturer, Shire plc, failed to complete required studies after the medicine reached the market. In September 2010, the FDA reversed its decision to remove midodrine from the market and allowed it to remain available to patients while Shire plc collected further data regarding the efficacy and safety of the drug. Shire announced on September 22, 2011, that it was withdrawing completely from supplying midodrine and leaving it to several generics to supply the drug. La midodrine (par exemple Amatine, ProAmatine, Gutron) est un médicament vasopresseur, antihypotensif. Elle se présente sous forme de poudre cristalline blanche, inodore, soluble dans l'eau, peu soluble dans le méthanol. Midodrin (Handelsname Gutron®) ist ein Arzneistoff, der zur Behandlung von hypotonen Kreislaufstörungen (orthostatische Hypotonie) dient. Es handelt sich dabei um ein Prodrug, dessen Metabolit Desglymidodrin den eigentlichen Wirkstoff darstellt. Der Arzneistoff wird in Form seines Hydrochlorids angewandt. 邁妥林是血管加压 / 抗低血压藥物，在1996年被美国食品药品监督管理局 （FDA）批准用于治疗自主神经功能障碍和姿位性低血压 。 FDA在2010年8月提议撤回该核准，因为制造商Shire plc在药物上市後后未能完成所需的研究 。 2010年9月，Shire plc收集了有关该药效果和安全性的进一步数据，FDA撤回上述提議並允许其继续供患者使用。 Shire plc于2011年9月27日宣布，它将继续与FDA合作以最终批准该药物。

dbp:chirality

dbr:Racemic_mixture

dbp:dailymedid

Midodrine

dbp:iupharLigand

7240

dbp:legalAu

S4

dbp:pregnancyAu

C

gold:hypernym

dbr:Agent

prov:wasDerivedFrom

wikipedia-en:Midodrine?oldid=1119963014&ns=0

dbo:wikiPageLength

12573

dbo:alternativeName

Amatine, Proamatine, Gutron, others

dbo:casNumber

42794-76-3

dbo:chEBI

6933

dbo:chEMBL

1076

dbo:drugbank

DB00211

dbo:fdaUniiCode

6YE7PBM15H

dbo:kegg

D08220

dbo:medlinePlus

a602023

dbo:pubchem

4195

foaf:isPrimaryTopicOf

wikipedia-en:Midodrine